Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses the role the new wave of biosimilars will have on rebate practices for both pharmacy benefit managers (PBMs) and payers.
The new wave of biosimilars will shed light on strategies for affordability and accessibility of these drugs coming to the market, says Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health.
Transcript
What are the regulatory and policy considerations related to this new wave of biosimilars and their impact on specialty pharmacy?
Sure, there are many! The first thing that comes to mind is kind of the closer look at rebate practices that PBMs [pharmacy benefit managers] and payers implement across their formularies and really, how they do business.
When we think about biosimilars and biosimilars coming to market and thriving in the market, they have to overcome what we call this rebate cliff, right? So, they have to beat the rebates that the reference product companies are offering to these payers and PBMs. And sometimes that's very challenging. And we'll see that as we see the adalimumab biosimilars come to market. We'll see some of that—not completely transparently—but you'll see it behind the scenes, that maybe not all plans are preferring a biosimilar. Although we all know they're more affordable or lower cost, we'll see that the brand or the reference product is being preferred on certain formularies.
There was an analysis done recently where it showed all the large payer PBMs and which ones of those preferred biosimilars more frequently. And it was very obvious that not all payers are the same in this regard.
Some payers have reference product first strategies and that is what is financially incentivizing to them and that's what makes financial sense to them at that time. As a specialty pharmacist, and knowing this market, and knowing the opportunities and the affordability that biosimilars intend to bring, we just really hope that some of these rebate policies and some of the closer look into some of those practices will really kind of shed a light on the fact that biosimilars do promise affordability and accessibility. But we have to think about the big picture about the long term, to really recognize the value that they're here to bring.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More